CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $4.26B, above the global median of $1.18B
- PositionGross margin is 24.3%, lower than 95% of its Medical Devices peers (median 59%)
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.26BUSDvs all stocks (USD)
Trailing P/E
34.30xvs Medical Devices peers
Revenue (TTM)
1.84BUSDvs all stocks (USD)
Profit Margin
6.97%vs Medical Devices peers
Beta
0.6130xvs all stocks
52-Week Change
16.69%vs all stocks
Market Capitalization
4.26BUSDvs all stocks (USD)
Enterprise Value
5.61BUSDvs all stocks (USD)
Trailing P/E
34.30xvs Medical Devices peers
Forward P/E
18.23xvs Medical Devices peers
PEG Ratio
-0.9826xvs Medical Devices peers
Price to Sales (TTM)
2.31xvs Medical Devices peers
Price to Book (MRQ)
2.48xvs Medical Devices peers
Enterprise to Revenue
3.04xvs Medical Devices peers
Enterprise to EBITDA
16.12xvs Medical Devices peers
Gross Margin
24.34%vs Medical Devices peers
Profit Margin
6.97%vs Medical Devices peers
Operating Margin
10.02%vs Medical Devices peers
Return on Assets (TTM)
3.86%vs Medical Devices peers
Return on Equity (TTM)
7.50%vs Medical Devices peers
Revenue (TTM)
1.84BUSDvs all stocks (USD)
Revenue per Share (TTM)
53.33USDUpdated Aug 27, 2026Quarterly Revenue Growth
-2.60%vs Medical Devices peers
Gross Profit (TTM)
481.70MUSDvs all stocks (USD)
EBITDA (TTM)
331.43MUSDvs all stocks (USD)
Net Income (TTM)
128.40MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-36.20%vs Medical Devices peers
Operating Cash Flow (TTM)
205.44MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
107.67MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Aug 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
1.85BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
1.35BUSDFY2025 · Dec 31, 2025Gross Profit
500.39MUSDFY2025 · Dec 31, 2025Operating Income
239.14MUSDvs all stocks (USD)
Pre-tax Income
125.40MUSDFY2025 · Dec 31, 2025Income Tax Expense
22.57MUSDFY2025 · Dec 31, 2025Net Income
102.81MUSDFY2025 · Dec 31, 2025EBIT
161.72MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
311.15MUSDFY2025 · Dec 31, 2025Research & Development
49.50MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
211.75MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
36.32MUSDFY2025 · Dec 31, 2025EPS (Basic)
2.96USDFY2025 · Dec 31, 2025EPS (Diluted)
2.89USDFY2025 · Dec 31, 2025Basic Shares Outstanding
34.73MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
34.73MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
102.81MUSDFY2025 · Dec 31, 2025Operating Cash Flow
224.31MUSDFY2025 · Dec 31, 2025Free Cash Flow
133.28MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
17.16MUSDFY2025 · Dec 31, 2025Income Tax Paid
28.22MUSDFY2025 · Dec 31, 2025Interest Paid
32.41MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
102.81MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
130.67MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-2.69MUSDFY2025 · Dec 31, 2025Stock-based Compensation
23.22MUSDFY2025 · Dec 31, 2025Other Non-cash Items
63.10MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-89.66MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-566.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-2.58MUSDFY2025 · Dec 31, 2025Capital Expenditures
-91.03MUSDFY2025 · Dec 31, 2025Net Acquisitions
-178.87MUSDFY2025 · Dec 31, 2025Other Investing Activity
123.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-269.78MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
1.28BUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-1.11BUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-50.01MUSDFY2025 · Dec 31, 2025Other Financing Charges
-87.94MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
39.91MUSDFY2025 · Dec 31, 2025Shares Outstanding
33.99MSharesUpdated Aug 27, 2026Float Shares
33.50MSharesUpdated Aug 27, 2026Shares Short
2.85MSharesUpdated Aug 27, 2026Short Ratio
1.98daysvs all stocks
Short % of Shares Outstanding
9.98%vs all stocks
% Held by Insiders
1.41%vs all stocks
% Held by Institutions
123.25%vs all stocks
Total Cash (MRQ)
21.38MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.6290USDUpdated Aug 27, 2026Total Debt (MRQ)
1.36BUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.7939xvs Medical Devices peers
Current Ratio (MRQ)
3.73xvs Medical Devices peers
Book Value per Share (MRQ)
50.56USDUpdated Aug 27, 2026Total Assets
3.41BUSDvs all stocks (USD)
Total Current Assets
770.10MUSDFY2025 · Dec 31, 2025Total Liabilities
1.66BUSDFY2025 · Dec 31, 2025Total Non-current Assets
2.64BUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
1.43BUSDFY2025 · Dec 31, 2025Total Current Liabilities
232.04MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
17.16MUSDFY2025 · Dec 31, 2025Accounts Receivable
346.08MUSDFY2025 · Dec 31, 2025Inventory
253.74MUSDFY2025 · Dec 31, 2025Accounts Payable
113.13MUSDFY2025 · Dec 31, 2025Short-term Debt
16.94MUSDFY2025 · Dec 31, 2025Deferred Revenue
5.21MUSDFY2025 · Dec 31, 2025Other Current Liabilities
13.88MUSDFY2025 · Dec 31, 2025Long-term Debt
1.30BUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
19.91MUSDFY2025 · Dec 31, 2025Common Stock (Book)
35.00KUSDFY2025 · Dec 31, 2025Retained Earnings
994.05MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
1.75BUSDvs all stocks (USD)
Treasury Stock
76.87MUSDFY2025 · Dec 31, 202552-Week Low
62.00USDUpdated Aug 27, 202652-Week High
126.14USDUpdated Aug 27, 202652-Week Change
16.69%vs all stocks
Beta
0.6130xvs all stocks
50-Day MA
105.44USDUpdated Aug 27, 2026200-Day MA
88.55USDUpdated Aug 27, 2026Avg 10-Day Volume
683.12KSharesUpdated Aug 27, 2026Avg 30-Day Volume
1.29MSharesUpdated Aug 27, 2026Diluted EPS (TTM)
3.65USDUpdated Aug 27, 2026Other Income / Expense
-71.43MUSDFY2025 · Dec 31, 20254 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
Where is this company structurally exposed?
Receivables Heavy and Growing
Money owed by customers keeps growing, and is much of its current assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 24.3%, lower than 95% of its Medical Devices peers (median 59%)Significant
Gross margin: 0.24Industry median: 0.59Industry P5: 0.26Peers compared: 60.00
Financial Health
Altman Z-Score 2.83: safe zoneNotable
Altman Z-Score: 2.83
High earnings qualityNotable
Earnings Quality Score: 1.59
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $4.26B, above the global median of $1.18BNotable
Market cap (USD): 4,259,203,614Global Median: 1,179,398,897.704
Revenue is $1.84B, above the global median of $534.05MNotable
Revenue (USD): 1,843,441,024Global Median: 534,052,387.958
Levered free cash flow is $107.67M, above the global median of $19.22MNotable
Levered free cash flow (USD): 107,673,376Global Median: 19,216,527.683
Companies that share the same coordination system — how they create, deliver, or capture value.
Tango Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Relay Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Veradermics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Indivior Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Chongqing Zhifei Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Humanwell Healthcare Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Shijiazhuang Yiling Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Xuanzhu Biopharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tianjin Pharmaceutical Da Ren Tang Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
China Medical System Holdings Limited
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Coforge Limited
4 interpretationsReceivables Heavy and GrowingRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthMulti-Year FCF With Growth And Margin
Harmony Biosciences Holdings, Inc.
3 interpretationsRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthMulti-Year FCF With Growth And Margin
Genpact Ltd.
4 interpretationsReceivables Heavy and GrowingRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthMulti-Year FCF With Growth And Margin